| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.7K | 7.5% | 17.3% |
| Total Income | 2.7K | 7.1% | 16.5% |
| Expenditure | 2.3K | 4.9% | 18.5% |
| PBT | 426.25 | 18.8% | 1.1% |
| Net Profit | 320.47 | 17.5% | 2.5% |
| OPM | 22.90% | 1.42pp | 1.97pp |
| NPM | 11.69% | 1.03pp | 2.28pp |
| EPS | 4.14 | 17.3% | 2.8% |
Revenue Up 17%, Profit Down 2% — The Execution Test Begins
Fortis posted strong 17.3% revenue growth but saw PAT decline 2.5% YoY. The gap reveals the real tension: can management convert expansion scale into profit growth when ESOP costs, new-unit ramp-up, and drug price controls are eating the margin gains?
On paper, Fortis delivered a confident quarter: revenue jumped to ₹2,735 Cr, hospitals grew 18.6%, occupancy ticked higher to 72%, and EBITDA margin expanded 30 basis points to 24.2%. But there is a disconnect that defines the read: profit fell 2.5% YoY despite revenue climbing 17.3%. That gap is not accounting noise — it is execution stress, and it matters.
₹320.5 Cr
-2.5% YoY
₹663 Cr
+19.2% YoY at 24.2%
₹2,735 Cr
+17.3% YoY
11.7%
vs prior ~15%, flow-through stalled
Where the margin went
EBITDA grew 19.2% but PAT declined. Three headwinds explain the disconnect. First, ESOP. Management flagged ₹140 Cr annual ESOP expense in FY27, which masks underlying operational margins. Second, new-unit ramp-up drag. Manesar and People Tree remain below target occupancy. Bangalore's Suguna acquisition sits at just 63% occupancy. FMRI, the flagship ₹200 Cr Delhi facility, has not yet been operationalized for profitability — critical oncology unit delayed to Q4 FY27. Third, near-term cost inflation and drug price controls. 137 oncology drugs are now under price caps; impact is unquantified but material. Management admitted it is 'very difficult' to assess the exact margin hit, but one-third of oncology revenue (~₹60–70 Cr) is exposed.
It is very difficult, this circular is very recent. We are still figuring out how it will be impacting the margins and all.
Management's claims: the report card
What changed on this call
Bed expansion accelerated. Suguna acquisition (1,000 beds, expandable to 1,150) brought forward; greenfield Delhi hospital (₹400 Cr) with 3–4 year timeline now on the roadmap. Total committed CAPEX ₹3,500 Cr over 3–3.5 years, up from prior ₹400-bed guidance. Margin guidance caveated. Previously confident '25% EBITDA by FY28' now heavily qualified. Management explicitly refrained from FY28 margin guidance due to drug price control uncertainties and new-unit ramp-up timing. Signal: near-term caution. Diagnostics guidance maintained. Held 12–13% FY27 growth target; Q2 achieved 12.2%. Wellness now 15% of diagnostics revenue (up from 13%), but overall volume growth muted at 5.8% YoY — offset by pricing gains.
The bull-bear ledger
Hospital segment +18.6% driven by occupancy gains (72%) and ARPP growth (+6.8%)
Multi-year bed expansion roadmap concrete: 500+ FY27, 2,000 by FY30 with committed ₹3,500 Cr CAPEX
EBITDA margin expanding (+30 bps YoY) despite new-unit drag; 15 hospitals at >20% margin (84% of revenue)
Profit declined 2.5% YoY despite 17.3% revenue growth — indicates execution friction
ESOP ₹140 Cr annual burden masks underlying margins; flow-through collapsed
New-unit integration below target: Bangalore 63% occupancy, FMRI OP pending, Manesar/People Tree in ramp-up
Drug price controls on 137 oncology drugs (one-third of oncology revenue exposed) — impact unquantified
Risks, ranked by how much they should concern a holder
Drug price controls on oncology (137 drugs)
HIGHMagnitude still unquantified. One-third of oncology revenue (~₹60–70 Cr) exposed. Management cannot model impact confidently. Could compress margins 100–150 bps if hit wholesale.
New-unit ramp-up execution delays
HIGHFMRI flagship ₹200 Cr project not yet profit-accretive; oncology unit delayed to Q4 FY27. Bangalore occupancy 63%. Raised execution risk on integration and occupancy ramp timelines.
Margin guidance deferral (no FY28 guidance)
MEDIUMManagement explicitly withheld FY28 margin guidance due to uncertainties. Signals caution on near-term margin recovery. Prior confidence on '25% by FY28' now qualified.
ESOP cost burden (~₹140 Cr FY27)
MEDIUMMasks underlying operational margin. Until ESOP winds down or is capitalized differently, reported PAT will remain pressured relative to EBITDA growth.
Leverage for ₹3,500 Cr CAPEX expansion
MEDIUMNet debt ₹2,188 Cr (0.87x EBITDA). CAPEX commitment requires debt/internal accrual. If revenue growth or margins miss, leverage could spike.
Forensic audit and regulatory overhang
LOWCourt-ordered 6-month audit; IHH stake increase possible but procedural. Minimal near-term constraint but overhang on strategic moves.
How the street is positioned
The market has been harsh. Stock at ₹774.55, down 29.86% from its all-time high, trading below all key moving averages (SMA20 ₹756, SMA50 ₹817, SMA200 ₹892). RSI at 48.6 (neutral) suggests oversold conditions are fading. Institutional flows reveal the tension: FII has trimmed 77 basis points (from 25.97% to 25.20% Q-o-Q), while DII has accumulated 88 basis points (31.35% to 32.23%). Promoter holding flat at 31.17%. The story: foreign funds are retreating on execution/margin concerns; domestic institutions are accumulating on valuation. The drawdown from the all-time high is steep — 30% is a significant repricing, and it reflects the market's own verdict: execution risk is real, and margin recovery is not yet credible.
1 · FMRI operationalization and oncology profitability
Flagship Delhi facility must commission radiation oncology unit by Q4 FY27. Profit contribution will signal execution capability on flagship ₹200 Cr project and validate multi-year bed expansion roadmap.
2 · Drug price controls impact quantification
Management must publish concrete margin impact (percentage points) of oncology price controls. Until then, FY28 guidance will remain uncertain. Q3 or Q4 clarity is critical to investor confidence.
3 · Bangalore and Manesar occupancy ramp-up
Bangalore at 63% is a red flag for integration speed. Manesar still in ramp-up. Next 2 quarters will show whether occupancy converges to network average (72%). Misses extend margin recovery timeline.
Fortis delivered a steady quarter on the headline: revenue growth is robust, EBITDA margin is expanding. But the profit miss — a 2.5% decline despite 17% revenue growth — reveals this is an execution test, not a growth story. The company is betting that new units (FMRI, Manesar, Bangalore) will mature, drug price controls will be quantified and managed, and ESOP costs will tail off. Until then, profit growth remains constrained. The stock's 30% drawdown from the all-time high has repriced it for caution; DII is accumulating, FII is retreating. The next two quarters will resolve whether this is a correction or a re-rating. Watch FMRI operationalization, drug price impact, and occupancy ramp. The number to track: adjusted PAT growth (stripping ESOP) — that will tell you whether management is executing or just expanding without profit.
Strong growth, margin pressure; PAT declined despite 17% revenue rise
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Margin guidance intact but qualified; near-term caution warranted. PAT miss signals integration/cost headwinds.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Fortis delivered strong 17% revenue growth and improving EBITDA margins, but profit declined 2.5% YoY—indicating execution stress from ESOP, new unit ramp-up, and drug price controls. Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.
₹2735 Cr
Revenue · +17.3% YoY₹320.5 Cr
Reported PAT · −2.5% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Hospital revenue 18.6% YoY to ₹2,340 Cr
METQ2 delivered supports this; hospital segment driving growth
Diagnostics 12.2% YoY growth to ₹448 Cr gross
METConfirmed in transcript; slower than hospital growth
EBITDA margins improving to 24.2% vs 23.9% YoY
METOperating EBITDA ₹663 Cr at 24.2% margin reported; YoY expansion
PAT growth 4% to ₹317 Cr pre-exceptional
OVERSTATEDDelivered PAT ₹320.5 Cr shows -2.5% YoY decline; exceptional items and NPM 11.7% suggest margin dilution
500+ beds expected FY27; 2,000 beds total expansion
METSuguna 110 beds + brownfield 200/year mentioned; 2,000-bed target by FY30
Earnings quality
What changed since the last call
Margin guidance qualification
NeutralManagement says 'margin guidance more or less intact' but refrained from FY28 guidance due to drug price control and ramp-up uncertainties. Cautious signal vs prior confidence.
Bed expansion acceleration
UpgradeNow targeting 500+ beds FY27 (vs 400 from prior call) with Suguna acquisition; 2,000-bed multi-year expansion by FY30 with clear mechanisms (greenfield ₹400 Cr, brownfield ₹3,500 Cr CAPEX committed)
Diagnostics growth guidance reiterated
MaintainedHeld 12-13% growth guidance for FY27; Q2 achieved 12.2%, wellness segment now 15% of revenue (vs 13% prior year), B2C mix 54% (vs 52%)
The Q&A
Analysts pressed hard on margins (Dhvani Shah, DSP; Neha Manpuria, BOFA), occupancy bottlenecks (Abdulkader Puranwala, ICICI), and acquisition strategy (Saion Mukherjee, Nomura). Management held ground on strategy but candidly conceded near-term margin uncertainties and drug price control impact, declining specific FY28 guidance.
Bed expansion greenfield timing — Neha Manpuria, Bank of America
Partial400-bed agreement with Seth Sunder Lal Jain Charitable Eye Hospital Society; partnership model; capex ₹3,500 Cr committed over brownfield/greenfield; 3-4 year timeline. One greenfield ₹400 Cr Delhi hospital coming over next 4 years.
Bangalore occupancy ramp-up — Abdulkader Puranwala, ICICI Securities
PartialSuguna is community/secondary care hospital; serves micro-market cluster alongside larger units. Different formats required for different patient profiles. Occupancy will improve; financially performing well. No near-term margin drag.
FMRI progress and profitability — Neha Manpuria, Bank of America
PartialNew block waiting for final approvals; should commission soon. Attracted good clinical talent in last months. Radiation oncology facility expected by February (Q4 FY27). Currently producing low-double-digit EBITDA; expect jump when oncology added.
Drug price control impact — Dhvani Shah, DSP Mutual Fund
DodgedVery difficult to assess exact quantum; circular very recent. One-third of oncology revenue exposed; some drugs profitable, some not. Calculating impact; will not give specific margin guidance until clarity. Expect margin flattish end-FY27, TBD for FY28.
Margin guidance and FY28 outlook — Neha Manpuria, Bank of America
DodgedMargin guidance 'more or less remains intact.' Challenges exist: FMRI OP pending, Manesar and People Tree in ramp-up, drug price controls uncertain. Will not comment on FY28 margin now; refrain from guidance due to uncertainty. Expect flattish EBITDA margin end-FY27.
Diagnostics growth bridging peer gap — Shyam Srinivasan, Goldman Sachs
PartialWellness now 15% of revenue (up from 13%), specialized growing. B2C up to 54% (from 52%). Focused on deep-market penetration, more centers, mid-teens growth target. Volume growth will improve with initiatives in specialized testing and B2C expansion.
IHH stake increase constraint — Atul Minocha, Independent Investor
AnsweredSupreme Court FY23 decision cleared IHH to increase stake. Forensic audit is separate; no constraint to IHH stake. Audit ordered by court, timeline 6 months. Constraint is IHH's decision on capex/dividend needs, not legal.
Gleaneagles O&M footprint and margin — Damayanti Kurai, HSBC
AnsweredOne year to stabilize operations; focused on recruiting doctors, facility upgrades, IT systems. Operations nearly flat; expect improvement from next year. Stabilization first, margin recovery later.
Guidance
Diagnostics FY27: 12-13% growth (reiterated)
MediumQ2 achieved 12.2%. Wellness acceleration and specialized testing expansion supporting mid-teens long-term, but near-term held at 12-13%.
Hospital bed expansion: 500+ beds FY27; 2,000 beds by FY30
HighSuguna 110 beds live; brownfield ~200 beds/year for next 2 years; greenfield ₹400 Cr Delhi hospital in pipeline. Committed CAPEX ₹3,500 Cr.
Hospital EBITDA 25% target FY28 (post-ESOP offset) — maintained
LowManagement says 'margin guidance more or less intact' but heavily qualified. New units (Manesar, People Tree) in ramp-up; FMRI OP pending. Refrained from FY28 margin guidance.
FY27 year-end EBITDA margin expected flattish
MediumCurrently 24.2% in Q2; Vivek said expect EBITDA margin 'flattish' end-FY27 due to ramp-up costs and drug price control uncertainties.
Committed CAPEX ₹3,500 Cr for brownfield/greenfield expansion
HighSpread over 3-3.5 years; includes Suguna (₹270 Cr), greenfield Delhi (₹400 Cr), brownfield facilities at Mohali, Shalimar Bagh, and others.
Risks the call surfaced
Regulatory & pricing
High137 oncology drugs under price cap; one-third of oncology revenue (~₹60-70 Cr) exposed. Impact magnitude unquantified. Management acknowledged 'very difficult' to assess.
Execution
HighFMRI flagship ₹200 Cr project not yet operationalized; Manesar and People Tree still in ramp-up with margin drag. Bangalore acquisition occupancy only 63%.
Operational
HighPAT declined 2.5% YoY despite 17% revenue growth. ESOP (₹140 Cr FY27) masking underlying margins. Drug price controls, ramp-up costs, and cost inflation pressuring profitability.
Financial
MediumNet debt ₹2,188 Cr (0.87x EBITDA). Committed CAPEX ₹3,500 Cr over 3-3.5 years requires debt/internal accrual. Risks if revenue growth or margins miss guidance.
Legal
LowForensic audit ordered by court; 6-month timeline. IHH stake increase possible but pending legal clarity. Overhang could delay strategic decisions.
Management
Score 7/10. Clear and candid on challenges. Refrained from speculative guidance (FY28 margin) pending drug price control clarity. Direct answers on most questions; some deflection on oncology margin impact timing. Mixed. Revenue growth 17.3% strong; EBITDA margin +30 bps YoY. But PAT flat/down and new unit ramp-up delayed vs history suggest execution friction. FMRI OP still pending.
1 · Q3 FY27
FMRI operational profitability; oncology impact clarity from drug price controls
2 · Q4 FY27
Manesar radiation oncology facility commissioning; People Tree ramp-up progress
3 · FY28
Two brownfield expansions (Mohali, Shalimar Bagh) completion; bed expansion to 2,000+ units
Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.
Execution on the Expansion Arc — Street at +45% on Capacity & Margin Play
Fortis reports Q2 FY27 on Nov 5 with Street expecting 16.6% revenue growth and 31.9% profit expansion. The story: ~2,000-bed pipeline ramp-up, Agilius diagnostics in margin recovery, and occupancy gains. Recent Suguna acquisition and leadership change are tactical; the game is on execution and EBITDA trajectory.
The Setup: Capacity Arc Meets Margin Inflection
Fortis is four quarters into a multi-year bed expansion targeting ~2,000 new beds through FY29. The thesis: rising occupancy from this capex cycle, paired with Agilius Diagnostics margin recovery after prior margin compression, should drive 31.9% profit growth in FY27 — well above the 16.6% revenue CAGR. This is a margin inflection story as much as a top-line play. Street has repriced it: consensus target is ₹1,118 (45% upside) on the back of 20 analyst calls driven by UBS, JPMorgan, and Citi all maintaining Buy with targets from ₹1,120–₹1,150.
~₹1,850–1,900 Cr
16.6% YoY growth baked into Street consensus; capacity additions offset seasonal demand patterns
~19–20.5% expected
200–250 bps expansion vs prior year on Agilius margin recovery + operational leverage
~₹210–230 Cr expected
31.9% profit growth assumes tax stability and no fresh one-time charges; watch forex/finance costs
Occupancy recovery underway
ARPOB (average revenue per occupied bed) expansion from new facility ramp-up and clinical mix shift to higher-acuity
Is Fortis On Track?
Yes, but with execution risk. The prior four quarters have tracked the expansion narrative: capex deployed on schedule, occupancy and ARPOB improving, and Agilius stabilizing margins after FY26 pressure. Q1 FY27 (reported in August) showed revenue growth of ~15–16% with margin improvement — on the glide path for the FY27 guidance. Street's 16.6% / 31.9% forecast is not aggressive; it's structural: bed additions + margin recovery. The long-term guide remains intact — 2,000 beds, ROI targets, and 500+ bps of margin expansion across the cycle. If Q2 holds the Q1 trajectory, the stock should consolidate toward the Street target.
What the Street Says
Since Last Quarter: Filings Scan
1 · Suguna Hospital Acquisition (₹277 Cr) — Oct 28
IHL (Fortis subsidiary) acquired Suguna Ramaiah Hospitals in Bengaluru — land, building, and operations. Strategic for bed count (adds ~200–250 beds) and geographic reach (South expansion). Near-term margin headwind from integration; validate amortization schedule and capex phasing in the earnings call.
2 · Chief Growth Officer Resignation — Oct 31
Dr. Ritu Garg (Chief Growth & Innovation Officer, SMP) resigned effective Oct 31 for external opportunity. Routine transition in healthcare; however, track continuity on growth initiatives (bed expansion, partnerships). No indication of strategy shift or internal friction.
3 · SLJ Charitable Eye Hospital Partnership — Sep 16
Fortis Hospotel signed definitive agreements to construct and operate a 400+ bed hospital for SLJ Society in Delhi. Non-consolidated partnership (not on balance sheet); demonstrates pipeline momentum but minimal impact on FY27 numbers (expect recognition post-FY28).
4 · Forensic Audit Proceedings — Ongoing
Delhi High Court ordered forensic audit on promoter shareholding dissipation (Sep 1). Supreme Court allowed the audit to proceed (Sep 25). IHH Healthcare (promoter) defending position. No operational impact, but track disclosures for any regulatory action; governance overhang should fade once audit completes.
5 · ESG Rating — Aug 24
Crisil assigned 'Strong' ESG rating (Crisil ESG 66, Core ESG 72). Positive signal on governance, environmental, and social practices — de-risks ESG-focused fund flows.
What to Watch on Result Day (Nov 5)
1 · EBITDA Margin Print & Trajectory
The margin call. If Q2 shows 19.5%+ EBITDA margin (vs ~19% in Q1), the Street target holds. If below 19%, repricing risk. Watch for: Agilius diagnostics operating margin separately; corporate cost absorption; and Suguna integration drag (offset by capex benefit timing).
2 · Bed Occupancy & ARPOB Trends
Operational leverage story hinges on: occupancy rates per center, ARPOB upticks from case-mix shift, and utilization of newly added beds. Track bed count additions in the quarter (should be 200–300 net new beds from organic + Suguna).
3 · Agilius Diagnostics Path to Recovery
Post-acquisition (Fortis acquired Agilius in FY24), margins have been under pressure. Q2 should show early signs of stabilization — cost synergies, pricing, and volume growth. If flat-to-negative, the profit-growth thesis is at risk.
4 · FY27 Guidance Reaffirmation & Suguna Integration Plan
Expect mgmt to reiterate 16–17% revenue growth and 30%+ profit growth for FY27 full-year. Crucially: clarify Suguna's contribution schedule, capex footprint, and integration timeline. If guidance narrowed or delayed, treat as caution.
5 · Free Cash Flow & Capex Runway
With 2,000-bed pipeline + Suguna acquisition, capex will be elevated. Validate that FCF remains positive and capex is tracking guidance. High capex without FCF visibility could pressure the balance sheet.
Fortis is 18 months into a multi-year margin and capacity inflection. Q2 FY27 is a checkpoint: if the quarter confirms ongoing bed ramp-up, EBITDA margin recovery (esp. Agilius), and occupancy gains, the Street's ₹1,118 target (45% upside) looks justified. The near-term risks — Suguna integration drag, leadership transition, and forensic audit overhang — are real but manageable. What moves the stock: margin print and guidance reaffirmation on the FY27 trajectory. If Q2 holds the Q1 glide path, Fortis should converge toward consensus. If margins disappoint or capex pressures FCF, repricing downward is swift in this space. Watch the operating metrics more than the revenue number.